Santhera becomes Founding Member of the Industry Advisory Council of the United Mitochondrial Disease Foundation
(Thomson Reuters ONE) -
Santhera Pharmaceuticals Holding AG /
Santhera becomes Founding Member of the Industry Advisory Council of the United
Mitochondrial Disease Foundation
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Liestal, Switzerland, April 25, 2017 - Santhera Pharmaceuticals (SIX: SANN)
announces Jodi Wolff, PhD, to represent Santhera as a founding member of the
United Mitochondrial Disease Foundation (UMDF) Industry Advisory Council (IAC)
with immediate effect.
Jodi Wolff, PhD, Director of Patient Advocacy and Medical Science Liaison at
Santhera Pharmaceuticals (USA), Inc., has been nominated by the UMDF to
represent Santhera as a member of the IAC based on her industry expertise and
advocacy work for patients with mitochondrial disease. As a member of the IAC,
Jodi Wolff becomes part of a broad stakeholder community that enables value-
added industry collaboration and helps drive key UMDF initiatives.
"The UMDF Industry Advisory Council (IAC) has been created to provide a platform
from which a diverse group of stakeholders can provide input for addressing key
priorities within the three pillars of the Mitochondrial Disease Roadmap
consisting of: diagnosis, therapeutic development and patient care," said
Charles A. Mohan Jr., CEO/Executive Director of UMDF. "We are excited to have
Santhera participate. Their valuable insight and advice will help guide us in
developing faster non-invasive diagnostics and potential therapies for
mitochondrial patients as well as develop a model for enhanced patient care. We
look forward to the continuation of our productive and mutually beneficial
working relationship."
Upon receiving the invitation from the UMDF to represent Santhera as a member of
the IAC, Jodi Wolff, PhD, commented: "I am thrilled to be a part of the UMDF
Industry Advisory Council and to continue Santhera's leadership in the field of
mitochondrial disease. We value our partnership with the UMDF and I look forward
to utilizing my experience to benefit families living with mitochondrial
disorders."
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan mitochondrial and neuromuscular diseases.
Santhera's lead product Raxone is authorized in the European Union, Norway,
Iceland and Liechtenstein for the treatment of Leber's hereditary optic
neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication
for Raxone, Santhera has filed a Marketing Authorization Application (MAA) in
the European Union and Switzerland. In collaboration with the US National
Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing
Raxone in a third indication, primary progressive multiple sclerosis (PPMS), and
omigapil for congenital muscular dystrophy (CMD), all areas of high unmet
medical need. For further information, please visit the Company's website
www.santhera.com.
Raxone(®) is a trademark of Santhera Pharmaceuticals.
About UMDF
Founded in 1996, the United Mitochondrial Disease Foundation (UMDF) works to
promote research and education for the diagnosis, treatment and cure of
mitochondrial diseases and to provide support for affected individuals and
families. Since its inception, the UMDF has funded nearly USD 11 million in
research, making it the leading non-governmental contributor of grants focused
solely on mitochondrial disease. The UMDF, based in Pittsburgh, PA, is a US-
national organization, represented around the world by thousands of members. For
more information about mitochondrial disease or the UMDF, visit www.umdf.org.
For further information, contact:
Thomas Meier, PhD, Chief Executive Officer Christoph Rentsch, Chief
Financial Officer
Phone +41 61 906 89 64 Phone
+41 61 906 89 65
thomas.meier(at)santhera.com
christoph.rentsch(at)santhera.com
Sue Schneidhorst, Head Group Communications
Phone +41 61 906 89 64
sue.schneidhorst(at)santhera.com
US investor contact US Public Relations
contact
Hans Vitzthum, LifeSci Advisors, LLC John Gillespie, Medical
Dynamics
Phone +1 212 915 2568 Phone
+1 646 599 8626
hans(at)lifesciadvisors.com
jgillespie(at)rxmedyn.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
# # #
News Release UMDF:
http://hugin.info/137261/R/2098337/794702.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 25.04.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 537966
Anzahl Zeichen: 6461
contact information:
Town:
Liestal
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 240 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Santhera becomes Founding Member of the Industry Advisory Council of the United Mitochondrial Disease Foundation"
steht unter der journalistisch-redaktionellen Verantwortung von
Santhera Pharmaceuticals Holding AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
